Clinical Trials
21 trialsNCT05988918 2026-05-14
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT01365169 2026-01-07
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT02230176 2025-04-20
OCCLURANDOM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT03736720 2025-01-30
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00655655 2024-08-21
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT02259725 2021-12-15
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
Phase 2 Completed
NCT01869725 2021-09-22
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Phase 2 Completed
NCT02806648 2018-01-23
PALBONET
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01056601 2017-12-28
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT00730483 2017-08-25
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Yale University
Phase NA Terminated
NCT02108782 2017-07-19
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT02273752 2017-02-03
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
Phase 2 Terminated
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT00416767 2016-05-30
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00002947 2014-07-02
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Yale University
Phase 1 Terminated
NCT00027638 2013-06-18
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00466856 2012-05-18
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated